Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals

被引：17

作者：

Nitulescu, Roy ^{[1
]}

Young, Jim ^{[1
,2
,3
]}

Saeed, Sahar ^{[3
]}

Cooper, Curtis ^{[4
,14
]}

Cox, Joseph ^{[1
,3
,16
]}

Martel-Laferriere, Valerie ^{[5
]}

Hull, Mark ^{[6
,19
]}

Walmsley, Sharon ^{[7
,8
,29
]}

Tyndall, Mark ^{[9
,27
]}

Wong, Alexander ^{[10
,30
]}

Klein, Marina B. ^{[1
,8
,20
,21
]}

Barrett, Lisa ^{[11
]}

Cohen, Jeff ^{[12
]}

Conway, Brian ^{[13
]}

Cote, Pierre ^{[15
]}

Gill, John ^{[17
]}

Haider, Shariq ^{[18
]}

Montaner, Julio ^{[19
,22
]}

Pick, Neora ^{[23
,24
]}

Rachlis, Anita

Rouleau, Danielle ^{[5
]}

Sandre, Roger ^{[25
]}

Sadr, Aida ^{[26
]}

Sanche, Steve ^{[28
]}

机构：

[1] McGill Univ, Hlth Ctr, Chron Viral Illness Serv, Dept Med,Div Infect Dis, Montreal, PQ, Canada

[2] Univ Hosp Basel, Basel Inst Clin Epidemiol & Biostat, Basel, Switzerland

[3] McGill Univ, Dept Epidemiol Biostat & Occupat, Montreal, PQ, Canada

[4] Univ Ottawa, Dept Med, Ottawa, ON, Canada

[5] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[6] St Pauls Hosp, Ctr Excellence HIV AIDS, Vancouver, BC, Canada

[7] Univ Hlth Network, Toronto, ON, Canada

[8] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada

[9] Univ British Columbia, Vancouver, BC, Canada

[10] Univ Saskatchewan, Dept Med, Regina, SK, Canada

[11] QEII Hlth Sci Ctr Clin Res, Halifax, NS, Canada

[12] Windsor Reg Hosp Metropolitan Campus, Windsor, ON, Canada

[13] PENDER Downtown Infect Dis Clin, Vancouver, BC, Canada

[14] Ottawa Hosp, Res Inst, Ottawa, ON, Canada

[15] Clin Quartier Latin, Montreal, PQ, Canada

[16] MUHC IDTC Montreal Gen Hosp, Montreal, PQ, Canada

[17] Southern Alberta HIV Clin, Calgary, AB, Canada

[18] McMaster Univ, Med Ctr, SIS Clin, Hamilton, ON, Canada

[19] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada

[20] McGill Univ, Hlth Ctr, Div Infect Dis, Montreal, PQ, Canada

[21] Chron Viral Illness Serv, Montreal, PQ, Canada

[22] Univ British Columbia, Vancouver, BC, Canada

[23] Univ British Columbia, Oak Tree Clin, Childrens & Womens Hlth Ctr British Columbia, Vancouver, BC, Canada

[24] Sunnybrook &Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada

[25] Hlth Sci North HAVEN Hemophilia Program, Sudbury, ON, Canada

[26] St Pauls Hosp, Native BC Hlth Ctr, Vancouver, BC, Canada

[27] Univ Ottawa, Infect Dis Div, Dept Med, Ottawa, ON, Canada

[28] Univ Saskatchewan, Saskatoon, SK, Canada

[29] Univ Hlth Network, Toronto, ON, Canada

[30] Univ Saskatchewan, Dept Med, Regina Gen Hosp, Regina, SK, Canada

来源：

INTERNATIONAL JOURNAL OF DRUG POLICY | 2019年 / 65卷

基金：

加拿大健康研究院;

关键词：

Treatment barriers; Direct-acting antivirals (DAAs); Disparities; HIV-hepatitis C co-infection; Treatment uptake; INJECT DRUGS; MEDICAID REIMBURSEMENT; HCV INFECTION; PEOPLE; COINFECTION; ACCESS; SOFOSBUVIR; TRANSMISSION; RESTRICTIONS; ELIMINATION;

D O I：

10.1016/j.drugpo.2018.08.012

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Background: Patients co-infected with HIV and hepatitis C virus (HCV) are a priority target for HCV treatment. The simplicity and efficacy of direct-acting antivirals (DAA) should help overcome patient, provider, and structural barriers to scaling up treatment. Methods: We estimated between-centre variation in DAA treatment uptake among 1734 patients enrolled at the 18 centres of the Canadian Co-Infection Cohort a prospective cohort of adults co-infected with HIV and HCV. We then compared this variation to that observed during the interferon era. Time to treatment uptake was modeled using a Weibull time-to-event model adjusting for centre and patient characteristics thought to have an impact on treatment initiation in the DAA era. Results: At the time of administrative censoring (December 31, 2016), 981 cohort participants were eligible for second-generation DAA therapy (HCV RNA positive after November 21, 2013) of vithom 278 initiated DAAs (16 patients per 100 person-years). Patients with low monthly income, Indigenous ethnicity, recent injection drug use, HCV genotype 3, or unknown HCV genotype were less likely to start treatment. After adjusting for patient characteristics, the estimated between-centre variance (o(2)) was 0.29 (95% credible interval [CrI]: 0.09-0.89), considerably lower than during the interferon era (o(2) = 0.87, 95% CrI: 0.49-1.5). This between -centre variance was further reduced by the addition of centre-level effects for jurisdiction (o(2) = 0.15, 95% CrI: 0.02-0.60). Conclusion: Much of the variation in treatment uptake between centres can now be attributed to regional differences. This suggests that after the introduction of DAAs, treatment barriers have shifted towards prescribing and reimbursement restrictions based on liver fibrosis, which vary by jurisdiction. The removal of these restrictions, however, will need to be paired with strategies to overcome patient-level barriers, which continue to prevent marginalized people and active substance users from accessing treatment.

引用

页码：41 / 49

页数：9

共 69 条

[21] Acute hepatitis C in HIV-negative men who have sex with men in the Netherlands and Belgium: a call for action [J].